<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052351</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000258196</org_study_id>
    <secondary_id>NCI-03-C-0005</secondary_id>
    <secondary_id>NCI-5191</secondary_id>
    <nct_id>NCT00052351</nct_id>
    <nct_alias>NCT00047398</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer</brief_title>
  <official_title>A Pilot Study Of Sequential Vaccinations With Recombinant Vaccinia-CEA(6D)-TRICOM, And Recombinant Fowlpox-CEA(6D)-TRICOM (B7.1/ICIAM-1/LFA-3) With Sargramostim (GM-CSF), In Conjunction With Standard Adjuvant Chemotherapy In High Risk Breast Cancer Patients Status Post Surgery With 4+ Or More Lymph Nodes And CEA Expressing Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a gene-modified virus may make the body build an immune&#xD;
      response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase&#xD;
      the number of immune cells found in bone marrow or peripheral blood. Drugs used in&#xD;
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Combining vaccine therapy with sargramostim and chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized clinical trial to study the effectiveness of vaccine therapy plus&#xD;
      sargramostim and combination chemotherapy in treating women who have undergone surgery for&#xD;
      stage II or stage III breast cancer that has spread to the lymph nodes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the immunological effects of 2 different schedules of vaccinia-CEA-TRICOM&#xD;
           vaccine, fowlpox-CEA-TRICOM vaccine, and sargramostim (GM-CSF) administered with&#xD;
           standard adjuvant chemotherapy in women with high-risk stage II or III breast cancer.&#xD;
&#xD;
        -  Compare the safety of these regimens in these patients.&#xD;
&#xD;
        -  Determine the feasibility of obtaining determinations of CD4 response in patients&#xD;
           treated with these regimens.&#xD;
&#xD;
        -  Compare disease-free survival of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Vaccinia-CEA-TRICOM: Beginning 2-3 weeks after surgery and before initiation of standard&#xD;
           adjuvant chemotherapy, all patients receive vaccinia-CEA-TRICOM vaccine subcutaneously&#xD;
           (SC) on day 1 and sargramostim (GM-CSF) SC on days 1-4 of week 1.&#xD;
&#xD;
        -  Fowlpox-CEA-TRICOM: Patients are treated on 1 of the following schedules:&#xD;
&#xD;
             -  Arm I: During chemotherapy, patients receive fowlpox-CEA-TRICOM vaccine SC on day 1&#xD;
                and GM-CSF SC on days 1-4 of weeks 2, 5, 8, 11, 14, 17, 20, and 23. After&#xD;
                chemotherapy, patients receive additional vaccinations on weeks 26, 38, and 50.&#xD;
&#xD;
             -  Arm II: Prior to chemotherapy, patients receive fowlpox-CEA-TRICOM vaccine SC on&#xD;
                day 1 and GM-CSF SC on days 1-4 of week 2. After chemotherapy, patients receive&#xD;
                additional vaccinations on weeks 26, 38, and 50.&#xD;
&#xD;
        -  Chemotherapy: Patients receive doxorubicin IV over 5-7 minutes and cyclophosphamide IV&#xD;
           over 30 minutes on day 1 of weeks 3, 6, 9, and 12. Patients then receive paclitaxel IV&#xD;
           over 3 hours on day 1 of weeks 15, 18, 21, and 24. Treatment continues in the absence of&#xD;
           disease progression (after at least 1 course of chemotherapy) or unacceptable toxicity.&#xD;
&#xD;
        -  Radiotherapy: Patients undergo radiotherapy during weeks 26-32 in the absence of disease&#xD;
           progression.&#xD;
&#xD;
      Patients with hormone-receptor positive tumors receive oral tamoxifen for 5 years beginning&#xD;
      on approximately week 32.&#xD;
&#xD;
      Patients are followed every 6 months for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 28 (14 per treatment arm) patients will be accrued for this&#xD;
      study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant fowlpox-CEA(6D)/TRICOM vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant vaccinia-CEA(6D)-TRICOM vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the breast&#xD;
&#xD;
               -  Stage II or III&#xD;
&#xD;
               -  At least 4 positive lymph nodes&#xD;
&#xD;
               -  No inflammatory ductal carcinoma&#xD;
&#xD;
          -  No positive lymph nodes by immunohistochemistry only&#xD;
&#xD;
          -  Carcinoembryonic antigen (CEA) expression, as indicated by 1 of the following:&#xD;
&#xD;
               -  At least 30% of tumor stains for CEA on immunohistochemistry&#xD;
&#xD;
               -  Elevated serum CEA (greater than 5 ng/mL) anytime during disease course&#xD;
&#xD;
          -  Must be HLA-A2 positive&#xD;
&#xD;
          -  Must have received prior vaccinia for smallpox immunization with 1 of the following as&#xD;
             evidence:&#xD;
&#xD;
               -  If age 25 and under, physician certification of prior vaccination&#xD;
&#xD;
               -  If over age 25, patient recollection and vaccination-site scar&#xD;
&#xD;
               -  Any age, detectable anti-vaccinia antibodies&#xD;
&#xD;
          -  No metastases by CT scan of chest, abdomen, and pelvis and a bone scan&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor status and progesterone receptor status known&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and SGPT no greater than 1.5 times ULN&#xD;
&#xD;
          -  Hepatitis B and C negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
          -  No proteinuria OR&#xD;
&#xD;
          -  Protein less than 1,000 mg per 24-hour urine collection&#xD;
&#xD;
          -  No hematuria&#xD;
&#xD;
          -  No abnormal sediment&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF at least 45% by echocardiogram or MUGA if either of the following are true:&#xD;
&#xD;
               -  History of cardiac disease&#xD;
&#xD;
               -  Received prior cardiotoxic chemotherapy&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No evidence of immunocompromised status&#xD;
&#xD;
          -  No autoimmune disease such as any of the following:&#xD;
&#xD;
               -  Autoimmune neutropenia, thrombocytopenia, or hemolytic anemia&#xD;
&#xD;
               -  Systemic lupus erythematosus&#xD;
&#xD;
               -  Sjogren's syndrome&#xD;
&#xD;
               -  Scleroderma&#xD;
&#xD;
               -  Myasthenia gravis&#xD;
&#xD;
               -  Goodpasture syndrome&#xD;
&#xD;
               -  Addison's disease&#xD;
&#xD;
               -  Hashimoto's thyroiditis&#xD;
&#xD;
               -  Active Graves' disease&#xD;
&#xD;
          -  No active or prior eczema or other eczematoid skin disorders&#xD;
&#xD;
          -  No other acute, chronic, or exfoliative skin conditions (e.g., atopic dermatitis,&#xD;
             burns, impetigo, varicella zoster, severe acne, or other open rashes or wounds)&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active infection within the past 3 days&#xD;
&#xD;
          -  No allergy to eggs&#xD;
&#xD;
          -  No history of allergy or untoward reaction to prior vaccination with vaccinia virus&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other serious illness&#xD;
&#xD;
          -  No other malignancy within the past 3 years except squamous cell or basal cell skin&#xD;
             cancer&#xD;
&#xD;
          -  No history of seizures, encephalitis, or multiple sclerosis&#xD;
&#xD;
          -  No active inflammatory bowel disease&#xD;
&#xD;
          -  Must be able to avoid close household contact with the following during and for 2&#xD;
             weeks after vaccinations:&#xD;
&#xD;
               -  Persons with active or prior eczema or other eczematoid skin disorders&#xD;
&#xD;
               -  Persons with any other acute, chronic, or exfoliative skin conditions (e.g.,&#xD;
                  atopic dermatitis, burns, impetigo, varicella zoster, severe acne, or other open&#xD;
                  rashes or wounds)&#xD;
&#xD;
               -  Pregnant or nursing women&#xD;
&#xD;
               -  Children under 5 years old&#xD;
&#xD;
               -  Immunodeficient or immunosuppressed persons (by disease or therapy), including&#xD;
                  those with HIV infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior doxorubicin, cyclophosphamide, or paclitaxel&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent steroids except the following:&#xD;
&#xD;
               -  Topical steroids&#xD;
&#xD;
               -  Inhaled steroids for moderate asthma&#xD;
&#xD;
               -  Dexamethasone prior to taxanes&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to more than 50% of the lymph nodes&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 2 weeks since prior surgery and recovered&#xD;
&#xD;
          -  No prior splenectomy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent anti-tumor therapies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip M. Arlen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2003</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

